

US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028

<https://marketpublishers.com/r/U5DFC3299822EN.html>

Date: October 2022

Pages: 300

Price: US\$ 3,300.00 (Single User License)

ID: U5DFC3299822EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028 Report Highlights:

Research Methodology

US Transdermal Patch Market Opportunity > USD 9 Billion

Market Availability, Dosage & Price Analysis On FDA Approved Patches

US Transdermal Patch Market Opportunity Assessment By Indication

US Transdermal Patch Clinical Pipeline Clinical Insight by Company, Drug Class, Indication & Phase

Comprehensive Insight On Approved Patches In Clinical Trials: > 40 Patch

Transdermal Patch Patent Insight

Insight On Marketed Transdermal Patch: > 30 FDA Approved Patch

Transdermal drug delivery which involves the delivery of drug into the systemic circulation across the skin has attracted physicians as well as patients owing to their several conferred advantages. These provide a specific, predetermined dose of

medication which is absorbed through the skin into the bloodstream. In addition, it also improves patient compliance; eliminate the hepatic first pass, and degradation in gastrointestinal tract. Over the last 30 years, many transdermal products have been launched in the US market and the demand has been grown as more and more example of successful treatment enters the mainstream.

These patches deliver drugs topically, where they are absorbed by the skin and into the bloodstream. These provide a consistent delivery of small amounts of a drug into the bloodstream over a long period of time. The length of wear time and the amount of drug delivered is different from patch to patch. To date, around 30 transdermal patches have entered the US market which is indicated for the management of wide range of diseases including cardiovascular diseases, neurological disorders, hormonal therapy, and other therapeutic conditions. Apart from this, several others are present in clinical trials, which are expected to enter the market during the forecast period.

As with any drug delivery system, there exists the potential for side effects with transdermal patches also which restrains their growth in market. The most likely side effect of a transdermal patch is irritated skin. Some wearers may have sensitive skin, making them more vulnerable to a reaction. Sensitivity can also result from the drug itself or the dose being too high. Apart from this, the high cost associated with the development of novel drug patch combination is anticipated to limit the investments in transdermal patches.

The US transdermal skin patch market is moderately competitive and the key players are focused on the adoption of various strategies including product innovation, product launches, and approvals. In addition, companies have also adopted collaboration, merger, and acquisitions as their development strategies to sustain the competitive environment in market. For instance, Canoa, a Delaware-based healthcare and pharmaceuticals company, had acquired ProSolus to enhance its position and development of new products in the transdermal space. The rising research and development activities in this field will propel the growth of market.

As per our report findings, the US transdermal patch market is expected to reach US\$ 9 Billion by 2028. Increasing demand for painless drug delivery, coupled with ease of self administration of drugs, is anticipated to fuel market growth. The market is also propelled by ongoing technological advancements in the field. Smart patches, for instance, allow auto-injection of medication and help in monitoring various body parameters. They also enable the transmission of patient generated data, thereby improving timing and accuracy of drug administration. Furthermore, collaboration

between pharmaceutical companies and drug delivery technology developers and preference for easy to use self administered drug delivery systems will create new market opportunities in coming years.

The report US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028 provides detailed analysis on the approved marketed products along with their price, dosage, and patch availability. The insights into ongoing clinical trials by company, drug class, indication, and phase are also reported. The major players covered in the US transdermal patches market report are AbbVie, Amneal Pharmaceuticals, Cumberland Pharmaceuticals, Glaxosmithkline, Hisamitsu Pharmaceutical and several others. On the basis of indication, the market opportunity is segmented into Alzheimer, Parkinson, Nicotine Replacement Therapy, Insulin, Vaccine, and Cardiovascular Disease.

Contents

1. RESEARCH METHODOLOGY

2. INTRODUCTION TO TRANSDERMAL PATCH

- 2.1 Classification of Transdermal Patches
- 2.2 Why There Exist Need for Transdermal Patches?
- 2.3 Mechanism of Transdermal Patch Drug Delivery

3. US TRANSDERMAL PATCH MARKET OVERVIEW

- 3.1 Current Market Scenario
- 3.2 Patch Market Opportunity Assessment By Indication
 - 3.2.1 Parkinson's Disease
 - 3.2.2 Alzheimer's Disease
 - 3.2.3 Female Contraceptive
 - 3.2.4 Nicotine Replacement Therapy
 - 3.2.5 Cardiovascular Disease
 - 3.2.6 Insulin
 - 3.2.7 Vaccine
- 3.3 US Transdermal Patch Market Future Trends

4. US TRANSDERMAL PATCH CLINICAL PIPELINE OVERVIEW

- 4.1 By Company
- 4.2 By Drug Class
- 4.3 By Indication
- 4.4 By Phase

5. CARDIOVASCULAR DISEASES TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS

- 5.1 Clonidine Transdermal Patch (Catapres–TTS)
- 5.2 Nitroglycerin Transdermal Patch

6. OPIOID DRUG CONTAINING TRANSDERMAL PATCHES - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS

- 6.1 Fentanyl Transdermal Patch (Duragesic)
- 6.2 Buprenorphine Transdermal Patch (Butrans Patch)

7. NEUROLOGICAL DISORDERS TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS

- 7.1 Selegiline Transdermal Patch (Emsam)
- 7.2 Scopolamine Transdermal Patch (Transderm-Scop)
- 7.3 Rivastigmine Transdermal Patch (Exelon)
- 7.4 Methylphenidate Transdermal Patch (Daytrana)
- 7.5 Asenapine Transdermal Patch (Secuado)
- 7.6 Rotigotine Transdermal Patch (Neupro)
- 7.7 Donepezil Transdermal Patch (Arlarity)
- 7.8 Dextroamphetamine Transdermal Patch (Xelstrym)

8. HORMONAL THERAPY TRANSDERMAL PATCH - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS

- 8.1 Estradiol Transdermal Patch
- 8.2 Testosterone Transdermal Patch (Androderm)
- 8.3 Ethinyl Estradiol & Norelgestromin Transdermal Patch
- 8.4 Estradiol/Levonorgestrel Transdermal Patch (Climara Pro)
- 8.5 Ethinyl Estradiol/Levonorgestrel (Twirla)

9. TRANSDERMAL PATCHES FOR OTHER CONDITIONS - US MARKET AVAILABILITY, DOSAGE & PRICE ANALYSIS

- 9.1 Nicotine Transdermal Patch (Nicoderm CQ/Harbitrol)
- 9.2 Oxybutynin Transdermal Patch (Oxytrol)
- 9.3 Sancuso (Granisetron)

10. US TRANSDERMAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION AND PHASE

- 10.1 Research
- 10.2 Preclinical
- 10.3 Phase-I
- 10.4 Phase-I/II
- 10.5 Phase-II

- 10.6 Phase-III
- 10.7 Preregistration
- 10.8 Registered

11. US MARKETED TRANSDERMAL PATCH CLINICAL INSIGHT BY COMPANY & INDICATION

12. US TRANSDERMAL PATCH MARKET DYNAMICS

- 12.1 Favorable Market Parameters
- 12.2 Commercialization Challenges

13. COMPETITIVE LANDSCAPE

- 13.1 AbbVie
- 13.2 Amneal Pharmaceuticals
- 13.3 Cumberland Pharmaceuticals
- 13.4 Glaxosmithkline
- 13.5 Hisamitsu Pharmaceutical
- 13.6 Lavipharm S.A.
- 13.7 Luye Pharma Group
- 13.8 Novartis
- 13.9 Nutriband
- 13.10 Pfizer
- 13.11 UCB
- 13.12 Viatris

List Of Tables

LIST OF TABLES

Table 2-1: Differences between Active & Passive Transdermal Patches

Table 2-2: Transdermal Patches for Various Disease Indications

Table 3-1: Features Required in Transdermal Patches

Table 3-2: US - Different Transdermal Drug Delivery Systems Available in Market

Table 3-3: US - Estimated Adoption Rates for Parkinson's Disease Transdermal Patches, 2021-2028

Table 3-4: Description of Neupro Patch for Parkinson's Disease

Table 3-5: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer's Disease, 2021-2028

Table 3-6: Transdermal Patches for Alzheimer's Disease

Table 3-7: Description of Ortho Evra Contraceptive Patch

Table 3-8: Difference Between Generic & Branded Transdermal Contraceptive Products

Table 3-9: US - Estimated Adoption Rates for Nicotine Transdermal Patches, 2022-2028

Table 3-10: Clonidine Patch - Difference Between Generic & Branded Transdermal Patch

Table 3-11: US - Estimated Adoption Rates for Hypertension Transdermal Patches, 2021-2028

Table 3-12: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2021-2028

Table 3-13: US - Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2021-2028

Table 6-1: Duragesic - Initial Dose Conversion from Other Opioids

Table 6-2: Butrans – Initial Dose Calculation using Previous Opioid (Morphine) Dosage

Table 7-1: Daytrana - Dose Increment Pattern for Treatment of ADHD

List Of Figures

LIST OF FIGURES

- Figure 2-1: Steps Involved in Transdermal Permeation
- Figure 2-2: Ideal Properties of Transdermal Patch
- Figure 2-3: Types of Commercially Available Transdermal Patch
- Figure 2-4: Properties of Transdermal Therapeutics
- Figure 2-5: Components of Transdermal Patch
- Figure 2-6: Types of Permeation Enhancers
- Figure 2-7: Schematic Representation of Iontophoresis
- Figure 2-8: Mechanism of Scopolamine Transdermal Patch
- Figure 2-9: Mechanism of Nicotine Transdermal Patch
- Figure 2-10: Mechanism of Female Contraceptive Transdermal Patch
- Figure 3-1: Advantages of Transdermal Patches
- Figure 3-2: Disadvantages of Transdermal Patches
- Figure 3-3: US - Major Reasons Behind Growth of Transdermal Patches
- Figure 3-4: US - Transdermal Patch Market (US\$ Billion), 2021 - 2028
- Figure 3-5: Potential Market Segments of Transdermal Drug Delivery Systems
- Figure 3-6: US - Susceptibility of Parkinson Disease Among Males and Females
- Figure 3-7: US - Estimated Increase in Parkinson's Disease Incidences
- Figure 3-8: US - Estimated Financial Impact of Parkinson's Disease on Economy (US\$ Billion)
- Figure 3-9: US - Parkinson's Disease Incidences, 2021-2028
- Figure 3-10: US - Estimated Sales of Neupro Patch (US\$ Million), 2020-2026
- Figure 3-11: US - Male & Female Suffering from Alzheimer's Disease (Million), 2021
- Figure 3-12: US - Shares of Male & Female Suffering from Alzheimer's Disease (%), 2021
- Figure 3-13: US - Percentage of Elderly People Suffering from Alzheimer's Disease, 2021
- Figure 3-14: US - Estimated Increase in Alzheimer's Incidences (Million), 2020, 2030, 2040 & 2050
- Figure 3-15: US - Estimated Incidences of Alzheimer's Disease (Million), 2021-2028
- Figure 3-16: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
- Figure 3-17: Benefits of Female Contraceptive Transdermal Drug Delivery System
- Figure 3-18: US - Decrease in Number of Smokers due to Nicotine Patch, 2005, 2013 & 2019
- Figure 3-19: US – Prevalence of Smokers by Gender (%), 2019

- Figure 3-20: Factors Responsible for Increased Consumption of Nicotine Patches
- Figure 3-21: US – Estimated Cases of Adult Hypertension (Million), 2019, 2025 & 2030
- Figure 3-22: US - Hypertension Incidences (Million), 2021-2028
- Figure 3-23: Rank of US among Different Diabetes Prone Countries
- Figure 3-24: US – Estimated Diabetic Population (Million), 2019, 2025, 2030 & 2045
- Figure 3-25: US – Undiagnosed & Diagnosed Diabetic Population (Million), 2019
- Figure 3-26: US – Undiagnosed & Diagnosed Diabetic Population (%), 2019
- Figure 3-27: US – Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 & 2045
- Figure 3-28: US – Estimated Diabetic Population (Million), 2021-2028
- Figure 3-29: Benefits of Insulin Transdermal Patch
- Figure 3-30: Drawback of Insulin Transdermal Patch
- Figure 3-31: Benefits of Vaccine Transdermal Patch
- Figure 3-32: Drawbacks of Vaccine Transdermal Patch
- Figure 3-33: US – Number of HIV Cases (Million), 2012, 2014 & 2018
- Figure 3-34: US – Estimated Number of HIV Cases (Million), 2020, 2025 & 2030
- Figure 3-35: US - Estimated HIV Incidences, 2021-2028
- Figure 4-1: US - Transdermal Patch Pipeline by Company (Numbers), 2022 till 2028
- Figure 4-2: US Transdermal Patch Pipeline by Drug Class (Numbers), 2022 till 2028
- Figure 4-3: US Transdermal Patch Pipeline by Indication (Numbers), 2022 till 2028
- Figure 4-4: US - Transdermal Patch Pipeline by Phase (%), 2021 till 2028
- Figure 4-5: US Transdermal Patch Pipeline by Phase (Numbers), 2022 till 2028
- Figure 5-1: Catapres-TTS – FDA Approval & First Generic Approval Year
- Figure 5-2: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US\$), September'2022
- Figure 5-3: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US\$), September'2022
- Figure 5-4: Catapres-TTS – Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US\$), September'2022
- Figure 5-5: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US\$), September'2022
- Figure 5-6: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US\$), September'2022
- Figure 5-7: Generic Clonidine Patch – Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US\$), September'2022
- Figure 5-8: Catapres-TTS – Recommended Initial & Incremented Dose (mg/Week)
- Figure 5-9: Catapres-TTS – Monthly & Annual Treatment Cost using 0.1mg Dose (US\$), September'2022
- Figure 5-10: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US\$), September'2022

Figure 5-11: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US\$), September'2022

Figure 5-12: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.3mg Film (US\$), September'2022

Figure 5-13: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US\$), September'2022

Figure 5-14: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.6mg Film (US\$), September'2022

Figure 5-15: Nitro-Dur – Price for 30 Films Supply & Price Per Unit of 0.8mg Film (US\$), September'2022

Figure 5-16: Nitro TD Patch A – Price for 30 Patch supply & Price Per Unit (US\$), September'2022

Figure 5-17: Generic Nitroglycerin Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US\$), September'2022

Figure 5-18: Generic Nitroglycerin Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US\$), September'2022

Figure 5-19: Generic Nitroglycerin Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US\$), September'2022

Figure 5-20: Generic Nitroglycerin Transdermal Patch – Price for 30 Films Supply & Price Per Unit of 0.6 mg Film (US\$), September'2022

Figure 6-1: Duragesic – FDA Approval Year by Dose

Figure 6-2: Duragesic – First Generic Approval Year by Dose

Figure 6-3: Duragesic - Price for 5 Patch Supply of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US\$), September'2022

Figure 6-4: Duragesic - Price per Unit of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US\$), September'2022

Figure 6-5: Generic Fentanyl Transdermal Patch - Price for 5 Patch Supply of Various Doses (US\$), September'2022

Figure 6-6: Generic Fentanyl Transdermal Patch - Price per Unit of Various Doses (US\$), September'2022

Figure 6-7: Butrans – FDA Approval Year by Dose

Figure 6-8: Butrans - Price for 4 Patch Supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US\$), September'2022

Figure 6-9: Butrans - Price per Unit of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US\$), September'2022

Figure 6-10: Generic Buprenorphine Transdermal Patch - Price for 4 Patch supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US\$), September'2022

Figure 7-1: Emsam - Price for 30 Patch Supply & Price Per Unit of Various Doses of Emsam Transdermal Patches (US\$), September'2022

Figure 7-2: Emsam - Monthly & Annual Treatment Cost of Parkinson's Disease (US\$), September'2022

Figure 7-3: Transderm-Scop – Price for a Supply of 4, 10 & 24 Patches of 1mg Transdermal Film (US\$), September'2022

Figure 7-4: Transderm-Scop – Price for a Supply of 4, 10 & 24 Patches of 1.5mg Transdermal Film (US\$), September'2022

Figure 7-5: Generic Scopolamine Transdermal Patch – Price for a Supply of 4, 10 & 24 Patches of 1mg Transdermal Film (US\$), September'2022

Figure 7-6: Exelon – Price for 30 Transdermal Patch Supply of Exelon (US\$), September'2022

Figure 7-7: Generic Rivastigmine Transdermal Patch – Price for a Supply of 30 Patches of Dose 4.6mg, 9.5mg & 13.3 mg (US\$), September'2022

Figure 7-8: Exelon – Initial & Maintenance Dose for the Treatment of Parkinson's Disease

Figure 7-9: Exelon – Monthly & Annual Treatment Cost for Treatment of Parkinson's Disease (US\$), September'2022

Figure 7-10: Daytrana – Patent Issue & Expiration Year

Figure 7-11: Daytrana - Price for 30 Transdermal Patch Supply of All Doses (US\$), September'2022

Figure 7-12: Secuado – Patent Issue & Expiration Year

Figure 7-13: Secuado – Price for 30 Transdermal Film & Price Per Unit of Various Dose Regimens (US\$), September'2022

Figure 7-14: Secuado – Recommended Initial & Incremented Dose (mg/Day)

Figure 7-15: US – Aderis Pharma's Neupro Patent Issue & Expiration Year

Figure 7-16: US – UCB's Neupro Patent Issue & Expiration Year

Figure 7-17: Neupro – Price for Supply of 30 Transdermal Films & Price Per Unit (US\$), September'2022

Figure 7-18: Neupro – Initial & Maximum Recommended Dose for Early Stage Parkinson (mg/day)

Figure 7-19: Neupro – Initial & Maximum Recommended Dose for Advanced Stage Parkinson (mg/day)

Figure 7-20: Global – Neupro Sales (US\$ Million), 2017-2022*

Figure 7-21: US – Neupro Sales (US\$ Million), 2017-2022

Figure 7-22: Global – Neupro Sales by Region (US\$ Million), 2021

Figure 7-23: Global – Neupro Sales by Region (US\$ Million), 2021

Figure 7-24: Adlarity - Price for 4 Transdermal Patch Supply of All Doses (US\$), September'2022

Figure 7-25: Adlarity – Recommended Initial & Incremented Dose (mg/day)

Figure 7-26: Xelstrym – Recommended Initial, Incremented and Maximum Doses

(mg/day)

Figure 8-1: Vivelle-Dot – FDA Approval & First Generic Approval Year

Figure 8-2: Vivelle-Dot - Price for a Supply of 8 Patches of Dose 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg (US\$), September'2022

Figure 8-3: Vivelle-Dot - Price per Unit of 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch (US\$), September'2022

Figure 8-4: Recommended Dose for Treatment of vaginal Atrophy, vasomotor Symptoms, & Postmenopausal Osteoporosis (mg/Day Twice a Week)

Figure 8-5: Minivelle – FDA Approval Year by Dose

Figure 8-6: Minivelle – FDA Approval & First Generic Approval Year

Figure 8-7: US – Minivelle Patent Issue & Expiration Year

Figure 8-8: Minivelle – Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US\$), September'2022

Figure 8-9: Minivelle - Recommended Dose by Indication (mg/Day)

Figure 8-10: Climara – FDA Approval Year by Dose

Figure 8-11: Climara – FDA Approval & First Generic Approval Year

Figure 8-12: Climara – Average Price for a Supply of 4 Transdermal Films & Price Per Unit of Various Doses (US\$), March'2021

Figure 8-13: Menostar – Price for a Supply of 4 Patches of Dose 14 mcg (US\$), September'2022

Figure 8-14: Generic Estradiol Transdermal Patch – Price Per 4 & 8 Films Supply & Price Per Unit of 0.025mg Film (US\$), September'2022

Figure 8-15: Generic Estradiol Transdermal Patch – Price for 4 & 8 Films Supply & Price Per Unit of 0.0375mg Film (US\$), September'2022

Figure 8-16: Generic Estradiol Transdermal Patch – Price for 4 and 8 Films Supply & Price Per Unit of 0.05mg Film (US\$), September'2022

Figure 8-17: Generic Estradiol Transdermal Patch – Price for 4 Supply & Price Per Unit of 0.06mg Film (US\$), September'2022

Figure 8-18: Generic Estradiol Transdermal Patch – Price for 4 and 8 Films Supply & Price Per Unit of 0.075mg Film (US\$), September'2022

Figure 8-19: Generic Estradiol Transdermal Patch – Price for 4 and 8 Films Supply & Price Per Unit of 0.1mg Film (US\$), September'2022

Figure 8-20: Androderm – Price for 60 Films Supply & per Unit Price of 2mg Transdermal Films (US\$), September'2022

Figure 8-21: Androderm – Price for 30 patch Supply & per Unit Price of 4mg Transdermal Patch (US\$), September'2022

Figure 8-22: Androderm – Recommended Initial & Maintenance Dose for Treatment of Hypogonadism (mg/day)

Figure 8-23: Ortho Evra – FDA approval & Withdrawal Year

Figure 8-24: Xulane – FDA Approval & First Generic Approval Year

Figure 8-25: Xulane – Price for a Supply of 3 Patches & Price Per Unit of 35mcg-150mcg Transdermal Patch (US\$), September'2022

Figure 8-26: Xulane – Recommended Schedule for Achieving Birth Control Effect (Days)

Figure 8-27: CombiPatch – Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US\$), September'2022

Figure 8-28: Climara Pro – Price for a Supply of 4 Films & Price Per Unit of Transdermal Film (US\$), September'2022

Figure 8-29: US – Twirla Patent Issue & Expiration Year

Figure 8-30: Twirla – Price for a Supply of 3 Patches & Price Per Unit of 30mcg-120mcg Transdermal Patch (US\$), September'2022

Figure 8-31: Twirla – Recommended Schedule for Achieving Birth Control Effect (Days)

Figure 9-1: Nicotine Transdermal Patch – FDA Approval Year by Product

Figure 9-2: Nicoderm CQ – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US\$), September'2022

Figure 9-3: Nicoderm CQ – Price per Unit of 7mg, 14mg & 21mg Transdermal Patch (US\$), September'2022

Figure 9-4: Harbitrol – Price for a Supply of 28 Transdermal Patches of Doses 7mg, 14mg & 21mg (US\$), March'2021

Figure 9-5: Generic Nicotine Patch – Price for a Supply of 7 Transdermal Patches of Doses 7mg, 14mg & 21mg (US\$), September'2022

Figure 9-6: Generic Nicotine Patch – Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US\$), September'2022

Figure 9-7: Generic Nicotine Patch – Price for a Supply of 28 Transdermal Patches of Doses 14mg & 21mg (US\$), September'2022

Figure 9-8: Nicoderm CQ – Recommended Dose & Treatment Schedule for Patients with Consumption More Than 10 Cigarette/Days (mg/day)

Figure 9-9: Nicoderm CQ – Recommended Dose & Treatment Schedule for Patients with Consumption of Less Than 10 Cigarette/Days (mg/day)

Figure 9-10: Nicoderm CQ – Full Treatment Cost for Patient with Daily Consumption of Less than 10 Cigarettes & More than 10 Cigarettes (US\$), March'2021

Figure 9-11: Oxytrol – Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US\$), September'2022

Figure 9-12: Oxytrol For Women – Price of 4 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US\$), September'2022

Figure 9-13: Oxytrol For Women – Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US\$), September'2022

Figure 9-14: Sancuso – Patent Issue & Expiration Year

Figure 12-1: Transdermal Patch Market Favorable Factors

Figure 12-2: Transdermal Patch Market Commercialization Challenges

I would like to order

Product name: US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/U5DFC3299822EN.html>

Price: US\$ 3,300.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U5DFC3299822EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970